Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABNCoV2 Vaccine in Seronegative and Seropositive Adults
NCT05077267Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Aug 2021
- Primary completion
- Feb 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of abncov2 in coronavirus disease 2019 (COVID-19), sponsored by Bavarian Nordic. Started Aug 2021; status: completed.
02
Drugs
abncov2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05077267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077267.